Home News Corporate moves

iX Biopharma aims for stronger growth momentum with Seelos licensing deal

Chloe Lim
Chloe Lim1/13/2022 12:54 PM GMT+08  • 8 min read
iX Biopharma aims for stronger growth momentum with Seelos licensing deal
iX Biopharma announces an outlicensing agreement worth more than $300 million (excluding royalties) with Seelos Therapeutics
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

iX Biopharma, a Singapore-listed specialty pharmaceutical company with expertise in drug delivery systems, has worked consistently on developing a wide range of medications, closing deals and partnerships, and improving investments in medical technology to capture a share of the multibillion-dollar global drug market.

On Nov 24 last year, the company announced an outlicensing agreement for its Wafermine drug worth more than $300 million (excluding royalties) with Nasdaq listed Seelos Therapeutics. Under the agreement, Seelos will provide the regulatory, clinical development and US market knowledge to register and commercialise Wafermine and other products related to ketamine — a medicine used to relieve pain.

Dr Janakan Krishnarajah, iX Biopharma’s COO cum chief medical officer, explains why Seelos was chosen. “Seelos has a portfolio of ketamine drugs, which means that they know the drug well, and know how to develop it and export it,” says Krishnarajah in an interview with The Edge Singapore. “They also had a strategy to build up ketamine as a franchise, which was important.”

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.